50,795 Shares in Prestige Consumer Healthcare Inc. $PBH Acquired by Deutsche Bank AG

Posted by Brian Himes on Aug 28th, 2026

Deutsche Bank AG purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) in the 2nd quarter, Holdings Channel reports. The firm purchased 50,795 shares of the company’s stock, valued at approximately $2,401,000.

A number of other large investors also recently modified their holdings of the company. UMB Bank n.a. raised its holdings in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth $35,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after purchasing an additional 236 shares in the last quarter. Finally, Danske Bank A S purchased a new position in Prestige Consumer Healthcare in the third quarter valued at $37,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

Positive Sentiment: Zacks projects earnings growth from $4.55 per share in FY2027 to $5.06 in FY2028 and $5.25 in FY2029, implying continued profit expansion for Prestige Consumer Healthcare.
Neutral Sentiment: The firm estimates quarterly EPS of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4. Its FY2027 forecast of $4.55 is broadly aligned with the current $4.56 consensus estimate.
Neutral Sentiment: Zacks maintained a “Hold” rating on PBH, signaling limited conviction that the projected earnings growth currently warrants a more bullish stance. Prestige Consumer Healthcare analyst estimates
Negative Sentiment: The update consists primarily of routine estimates for periods extending through FY2029, rather than a fresh earnings beat, guidance increase, or strategic announcement. That lack of a new positive catalyst may be weighing on the stock in the near term.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on PBH shares. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $70.75.

Get Our Latest Stock Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Trading Down 1.7%

NYSE PBH opened at $51.27 on Friday. The firm’s fifty day moving average is $50.11 and its two-hundred day moving average is $54.64. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The firm has a market cap of $2.43 billion, a PE ratio of 14.36, a P/E/G ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same quarter in the prior year, the firm earned $0.90 earnings per share. The business’s quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

(Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).